Pathai

Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day

Retrieved on: 
Thursday, December 15, 2022
RNA, Immunotherapy, Society, Tumor microenvironment, Health, Software, Akoya, Inflammation, Ecosystem, Pathai, Annual general meeting, Workflow, Society for Immunotherapy of Cancer, HT, Neuroscience, Data analysis, Organization, HIV disease progression rates, SITC, Biomarker, Precision medicine, Automation, Architecture, Biology, Risk management, Microscope, Medical imaging, 3D printing, Panel

MARLBOROUGH, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today highlighted the latest wave of spatial biology innovations, new products, and partnerships that further accelerate and simplify spatial signature discovery and validation, at its second annual Spatial Day event. Company leadership and leading scientists came together to discuss advancements in spatial biology and the progress towards delivering spatial signatures to advance the field of precision medicine.

Key Points: 
  • New products and partnerships further accelerate and simplify identification of actionable spatial signatures, creating unprecedented opportunities to improve patient outcomes
    MARLBOROUGH, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today highlighted the latest wave of spatial biology innovations, new products, and partnerships that further accelerate and simplify spatial signature discovery and validation, at its second annual Spatial Day event.
  • Company leadership and leading scientists came together to discuss advancements in spatial biology and the progress towards delivering spatial signatures to advance the field of precision medicine.
  • At this year’s Spatial Day, the company introduced a suite of ready-to-use PhenoCode™ panels to accelerate the adoption and utilization of the company’s spatial phenotyping solutions for discovery and translational research.
  • As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping.

Artificial Intelligence (AI)-Based Digital Pathology Solutions Market to Record Rapid Growth with CAGR of 7.67% by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Thursday, December 8, 2022
Laboratory, MiCK assay, Breast cancer, Oradel Industrial Center, Cleveland Clinic, Gastrointestinal cancer, Cancer, Pathai, Drug development, VNA, Digital pathology, Algorithm, Colorectal cancer, Diagnosis, Perception, Convolutional neural network, DP, Digital, Lung cancer, Lymph, AI, Cervical cancer, Pathology, Growth, Prostate cancer, Data management, Colorectal surgery, Type, Roche, Artificial neural network, Investment, Artificial intelligence, Marie Cassidy, Tribune, Workflow, Patient, History of Cleveland Clinic, Bangladesh Technical Education Board, Recurrent neural network, Artificiality, GE Healthcare, Medical device, Medical imaging, Research

According to the latest research by InsightAce Analytic, the global AI-Based Digital Pathology solutions market is expected to grow with a CAGR of 7.67% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global AI-Based Digital Pathology solutions market is expected to grow with a CAGR of 7.67% during the forecast period of 2022-2030.
  • During the forecast period, digital pathology solutions will continue to drive market revenue growth due to the increasing use of digital pathology solutions in drug development and biomarker identification.
  • Additionally, a slow rate of technological advancement may hinder the growth of AI-based digital pathology solutions on the market.
  • Global AI-Based Digital Pathology Solutions Market, by Type of Neural Network, 2022-2030 (Value US$ Mn)

Artificial Intelligence (AI)-Based Digital Pathology Solutions Market to Record Rapid Growth with CAGR of 7.67% by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Thursday, December 8, 2022
Laboratory, MiCK assay, Breast cancer, Oradel Industrial Center, Cleveland Clinic, Gastrointestinal cancer, Cancer, Pathai, Drug development, VNA, Digital pathology, Algorithm, Colorectal cancer, Diagnosis, Perception, Convolutional neural network, DP, Digital, Lung cancer, Lymph, AI, Cervical cancer, Pathology, Growth, Prostate cancer, Data management, Colorectal surgery, Type, Roche, Artificial neural network, Investment, Artificial intelligence, Marie Cassidy, Tribune, Workflow, Patient, History of Cleveland Clinic, Bangladesh Technical Education Board, Recurrent neural network, Artificiality, GE Healthcare, Medical device, Medical imaging, Research

According to the latest research by InsightAce Analytic, the global AI-Based Digital Pathology solutions market is expected to grow with a CAGR of 7.67% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global AI-Based Digital Pathology solutions market is expected to grow with a CAGR of 7.67% during the forecast period of 2022-2030.
  • During the forecast period, digital pathology solutions will continue to drive market revenue growth due to the increasing use of digital pathology solutions in drug development and biomarker identification.
  • Additionally, a slow rate of technological advancement may hinder the growth of AI-based digital pathology solutions on the market.
  • Global AI-Based Digital Pathology Solutions Market, by Type of Neural Network, 2022-2030 (Value US$ Mn)

Day Zero Diagnostics Welcomes Healthcare Business Leader Gail Marcus to its Board

Retrieved on: 
Wednesday, November 9, 2022
Zero, Infection, Diagnosis, MBA, Review, NTRA, UnitedHealth Group, Lancet, Subclinical infection, Commonwealth Education Trust, DHA, Pathai, Patient, MSE, Medical University of South Carolina, Board, Caris, Drug resistance, Population health, Massachusetts General Hospital, Hofstra University, Machine learning, WGS, Death, Harvard University, Cure, CIGNA, Sepsis, BA, University, Wharton School of the University of Pennsylvania, University of Pennsylvania, Culture, Board of directors, Wesleyan University, Leadership, Nasdaq, Population, Medical school, Health, CEO, Vaccine, Management, Pharmaceutical industry, Antibiotics, Engineering

"We are pleased to welcome Gail Marcus to the Day Zero Diagnostics Board of Directors.

Key Points: 
  • "We are pleased to welcome Gail Marcus to the Day Zero Diagnostics Board of Directors.
  • "I'm excited to work with the Day Zero Diagnostics executive team and board as the company continues to advance its disruptive approach to infectious disease diagnosis, with the mission to help curb the growing global healthcare crisis of antibiotic resistance," said Gail Marcus.
  • Day Zero Diagnostics most recently announced an additional $8.2 million in non-dilutive funding from CARB-X for the development of its sequencing based diagnostic system.
  • Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital.

PathAI to Present on AI Models Supporting Advances in Oncology Research at Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Science, Biotechnology, Research, Oncology, Health, Artificial Intelligence, Technology, Clinical Trials, Diagnosis, Patient, Society, Precision medicine, Deep learning, Stomach, Immunotherapy, Melanoma, Cancer, GNN, CD8, Machine learning, Hepatocellular carcinoma, Large-cell lung carcinoma, SITC, Squamous cell carcinoma, Drug development, Pancreatic cancer, Immunophenotyping, ML, Head, Pathology, Colorectal cancer, Neoplasm, Cell, Cholangiocarcinoma, Research, Tumor microenvironment, Medical device, Medical imaging, Pathai, NSCLC

PathAI has since expanded upon that research and will share data demonstrating how their newly developed ML-based models quantify CD8+ lymphocytes and CD8 topology classifiers across seven cancer types: NSCLC, urothelial carcinoma, head and neck squamous cell carcinoma, gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma.

Key Points: 
  • PathAI has since expanded upon that research and will share data demonstrating how their newly developed ML-based models quantify CD8+ lymphocytes and CD8 topology classifiers across seven cancer types: NSCLC, urothelial carcinoma, head and neck squamous cell carcinoma, gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma.
  • Our latest results support and further extend our research in immuno-oncology for multiple disease areas, said Dr. Mike Montalto, Chief Scientific Officer at PathAI.
  • This is another big step forward in innovating and improving pathology research, future drug development, and, ultimately, patient outcomes.
  • Additionally, PathAI has developed a new deep-learning-based method for the analysis of whole slide image multiplex immunofluorescence (mIF) data in NSCLC.

PathAI to Present Recent Advances in Applying AI-Powered Pathology Towards Liver Disease at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting

Retrieved on: 
Wednesday, November 2, 2022
Biotechnology, Technology, Other Health, Health, General Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Science, Liver, Histology, Fatty liver disease, American Association for the Study of Liver Diseases, Partnership, Cancer, Intelligence, Research, ML, Liver disease, Gene expression, Fibrosis, Pathology, Marie Cassidy, Institute of Liver and Biliary Sciences, NASH, Technology, Deep learning, Time, Machine learning, AASLD, MT, Novo Nordisk, Precision medicine, Drug development, CRN, Gilead Sciences, Association, Solution, American Association, Diagnosis, Medical device, Medical imaging, Patient, Pathai

The latest research from our team aimed to explore the variabilities that exist in pathologist review of liver biopsies.

Key Points: 
  • The latest research from our team aimed to explore the variabilities that exist in pathologist review of liver biopsies.
  • Our findings indicate that integrating artificial intelligence solutions into this process can greatly enhance the consistency and accuracy of these assessments, said Dr. Mike Montalto, Chief Scientific Officer at PathAI.
  • This approach will naturally extend to improving NASH drug development which is critical to addressing a large unmet medical need for patients.
  • PathAI continues to drive NASH research forward to support the long-term need for more granular assessment of liver biopsies.

PathAI Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

Retrieved on: 
Thursday, August 25, 2022
Technology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Data Management, Artificial Intelligence, Oncology, CEO, BMS, Technology, Immunotherapy, Cancer, Bristol Myers Squibb, Translational medicine, Precision medicine, CD8, Society for Immunotherapy of Cancer, Pathology, Head, Diagnosis, Multimedia, Journal, Deep learning, IHC, Annual general meeting, Fibrosis, PD, Health, The Society, PD-L1, Drug development, AI, Patient, SITC, Pharmaceutical industry, Pathai, Immunology

PathAI, a global leader in AI-powered pathology, today announced a multi-year expanded collaboration agreement with Bristol Myers Squibb.

Key Points: 
  • PathAI, a global leader in AI-powered pathology, today announced a multi-year expanded collaboration agreement with Bristol Myers Squibb.
  • View the full release here: https://www.businesswire.com/news/home/20220825005063/en/
    PathAI Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb (Graphic: Business Wire)
    We look forward to collaborating with PathAI to expand the potential application of AI in the drug development process to include translational research, clinical trials and diagnostic advancements, said Robert Plenge, M.D., Ph.D., Bristol Myers Squibb Senior Vice President and Head, Immunology, Cardiovascular and Fibrosis Thematic Research Center and Head, Translational Medicine.
  • Bristol Myers Squibb and PathAI will utilize AI pathology models with the potential to de-risk therapeutic development across the Bristol Myers Squibbs pipeline by better identifying patient populations.
  • In addition, Bristol Myers Squibb and PathAI plan to leverage these models to obtain key insights to help enhance patient segmentation in clinical trials across multiple disease indications.

VISTAPATH AND PATHAI COLLABORATE TO VALIDATE AUTOMATED TISSUE GROSSING PLATFORM

Retrieved on: 
Thursday, July 14, 2022
Technology, Compliance, Multimedia, Artificial intelligence, Patient, CEO, Diagnosis, Entrepreneurship, Marie Cassidy, Workflow, Pathology, AI, FDA, ISO27001, Pathai, Partnership, Medical device, Medical imaging, Sentinel

VistaPath Sentinel is the world's first automated tissue grossing platform.

Key Points: 
  • VistaPath Sentinel is the world's first automated tissue grossing platform.
  • The Sentinel is a first-of-its-kind tissue grossing platform that automates the process of receiving, assessing, and processing tissue samples.
  • Our work with PathAI has proven our ability to modernize this critical lab process," said Timothy Spong, CEO of VistaPath.
  • For customers like PathAI, the Sentinel adds another level of sophistication to their workflow by providing automated grossing, making the process faster, cheaper and with fewer errors.

PathAI Appoints Brandon Eldredge as Chief Financial Officer

Retrieved on: 
Thursday, July 14, 2022
Oncology, Data Management, Health, Technology, Clinical Trials, Pharmaceutical, Biotechnology, Mass General Brigham, Precision medicine, Strategic management, Thermo Fisher Scientific, Motional, Senior, CEO, Aptiv, Barclays Investment Bank, Diagnosis, Mass, Pathology, AI, Deep learning, Intelligence, Growth, Cancer, Mobility, Syneos Health, Improved Mobile Telephone Service, Management, Pathai

PathAI , a global leader in AI-powered pathology, today announced that it has appointed Brandon Eldredge as Chief Financial Officer.

Key Points: 
  • PathAI , a global leader in AI-powered pathology, today announced that it has appointed Brandon Eldredge as Chief Financial Officer.
  • Brandons finance experience spans strategy, business development, mergers and acquisitions, and partnerships for a wide range of high-growth healthcare and technology organizations, said Andy Beck, Co-founder and CEO of PathAI.
  • Eldredge joins PathAI most recently from Mass General Brigham, where he served as Chief Clinical Business Officer overseeing the creation and execution of the organization's strategic growth initiatives.
  • Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine.

Aditya Khosla, PhD, Joins Iterative Scopes as Chief Technology Officer

Retrieved on: 
Tuesday, June 21, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Doctor of Philosophy, Pathology, Google, Iteration, CTO, GI, Technology, CEO, Gastroenterology, MIT, MBBS, Precision medicine, Gastrointestinal disease, Engineering, Disease, Colorectal cancer, IBD, Patient, Inflammatory bowel disease, Deep learning, Multimedia, Machine learning, AI, Management, Risk management, Medical device, Pathai

Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that Aditya Khosla, PhD, has joined its leadership team as Chief Technology Officer, and a member of the board of directors.

Key Points: 
  • Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that Aditya Khosla, PhD, has joined its leadership team as Chief Technology Officer, and a member of the board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20220621005237/en/
    Aditya Khosla, PhD, Chief Technology Officer of Iterative Scopes (Photo: Business Wire)
    We are thrilled to welcome Dr. Khosla to the Iterative Scopes team, says Jonathan Ng, MBBS, founder and CEO of Iterative Scopes.
  • In his role as CTO, Dr. Khosla will lead Iterative Scopes machine learning, product management, and software engineering teams.
  • I am incredibly excited for Aditya to bring his scientific leadership and operational expertise to Iterative Scopes to unlock a new generation of AI tools in gastroenterology.